669,702 Shares in MeiraGTx Holdings plc (NASDAQ:MGTX) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH purchased a new stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 669,702 shares of the company’s stock, valued at approximately $2,795,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Knoll Capital Management LLC bought a new stake in MeiraGTx during the 3rd quarter valued at approximately $5,212,000. Royce & Associates LP increased its position in MeiraGTx by 5.3% in the 3rd quarter. Royce & Associates LP now owns 795,392 shares of the company’s stock worth $3,317,000 after buying an additional 40,000 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of MeiraGTx by 14.6% during the second quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock worth $1,949,000 after buying an additional 58,854 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of MeiraGTx by 3.7% in the first quarter. Vanguard Group Inc. now owns 323,891 shares of the company’s stock valued at $1,966,000 after acquiring an additional 11,470 shares during the period. Finally, Privium Fund Management B.V. grew its stake in shares of MeiraGTx by 4.9% in the third quarter. Privium Fund Management B.V. now owns 213,960 shares of the company’s stock worth $892,000 after acquiring an additional 10,000 shares during the last quarter. 67.48% of the stock is owned by institutional investors and hedge funds.

MeiraGTx Price Performance

Shares of NASDAQ:MGTX opened at $6.64 on Tuesday. The firm has a market capitalization of $518.92 million, a PE ratio of -5.60 and a beta of 1.24. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86. MeiraGTx Holdings plc has a 1-year low of $3.85 and a 1-year high of $7.60. The business’s 50 day moving average is $5.54 and its 200-day moving average is $4.87.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Chardan Capital reiterated a “buy” rating and set a $36.00 target price on shares of MeiraGTx in a research note on Monday, November 18th. Royal Bank of Canada upped their price objective on shares of MeiraGTx from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th.

MeiraGTx Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.